{1 (aprepitant 125 MG Oral Capsule [Emend]) / 2 (aprepitant 80 MG Oral Capsule [Emend]) } Pack [Emend Tri-Fold Pack]
aprepitant
RxCUI: 754509
What the CMS Formulary Data Shows for {1 (aprepitant 125 MG Oral Capsule [Emend]) / 2 (aprepitant 80 MG Oral Capsule [Emend]) } Pack [Emend Tri-Fold Pack]
Per the CMS 2026 Part D formulary file, {1 (aprepitant 125 MG Oral Capsule [Emend]) / 2 (aprepitant 80 MG Oral Capsule [Emend]) } Pack [Emend Tri-Fold Pack] (RxNorm concept RXCUI 754509, generic name aprepitant) appears on 1 distinct formulary file spanning 2 Medicare Part D plan offerings - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 1, with a cross-plan average of Tier 1.
Real-world access to {1 (aprepitant 125 MG Oral Capsule [Emend]) / 2 (aprepitant 80 MG Oral Capsule [Emend]) } Pack [Emend Tri-Fold Pack] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 22 Part D beneficiaries filled {1 (aprepitant 125 MG Oral Capsule [Emend]) / 2 (aprepitant 80 MG Oral Capsule [Emend]) } Pack [Emend Tri-Fold Pack] in 2023, with total plan-and-beneficiary spending of $61,588 and an average per-beneficiary annual cost of $2,799.45. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry {1 (aprepitant 125 MG Oral Capsule [Emend]) / 2 (aprepitant 80 MG Oral Capsule [Emend]) } Pack [Emend Tri-Fold Pack] today.
Coverage Details
- Formularies covering
- 1
- Plans covering
- 2
- Coverage rate
- 0%
- Tier range
- Tier 1, Preferred Generic
- Average tier
- Tier 1, Preferred Generic
Restrictions
- Prior authorization required
- 100% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 22
- Total spending
- $61,588
- Avg per beneficiary
- $2,799.45
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering {1 (aprepitant 125 MG Oral Capsule [Emend]) / 2 (aprepitant 80 MG Oral Capsule [Emend]) } Pack [Emend Tri-Fold Pack]
2 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | HAMASPIK, INC. | T1 | Yes | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | HAMASPIK, INC. | T1 | Yes | $34.50 | NY |
Frequently Asked Questions
Is {1 (aprepitant 125 MG Oral Capsule [Emend]) / 2 (aprepitant 80 MG Oral Capsule [Emend]) } Pack [Emend Tri-Fold Pack] covered by Medicare Part D?
Yes, {1 (aprepitant 125 MG Oral Capsule [Emend]) / 2 (aprepitant 80 MG Oral Capsule [Emend]) } Pack [Emend Tri-Fold Pack] is covered by 2 Medicare Part D plans (0% of all Part D formularies).
What tier is {1 (aprepitant 125 MG Oral Capsule [Emend]) / 2 (aprepitant 80 MG Oral Capsule [Emend]) } Pack [Emend Tri-Fold Pack] on Medicare Part D plans?
{1 (aprepitant 125 MG Oral Capsule [Emend]) / 2 (aprepitant 80 MG Oral Capsule [Emend]) } Pack [Emend Tri-Fold Pack] averages Tier 1 across Part D plans, ranging from Tier 1 to Tier 1.
Does {1 (aprepitant 125 MG Oral Capsule [Emend]) / 2 (aprepitant 80 MG Oral Capsule [Emend]) } Pack [Emend Tri-Fold Pack] require prior authorization?
100% of Part D formularies require prior authorization for {1 (aprepitant 125 MG Oral Capsule [Emend]) / 2 (aprepitant 80 MG Oral Capsule [Emend]) } Pack [Emend Tri-Fold Pack]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on {1 (aprepitant 125 MG Oral Capsule [Emend]) / 2 (aprepitant 80 MG Oral Capsule [Emend]) } Pack [Emend Tri-Fold Pack]?
In 2023, total Medicare Part D spending on {1 (aprepitant 125 MG Oral Capsule [Emend]) / 2 (aprepitant 80 MG Oral Capsule [Emend]) } Pack [Emend Tri-Fold Pack] was $61,588, covering 22 beneficiaries. The average spend per beneficiary was $2,799.45.
Read our methodology - how this data is sourced, computed, and verified.